Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
Discovering and developing life-changing treatments for patients is our focus. By tailoring biotherapeutic performance using novel protein and gene therapies, we are well-positioned to address unmet medical needs and find treatments for a wide range of diseases and disorders.
Learn MoreHighly specialized enzymes can address many challenges faced in DNA and RNA synthesis, NGS, and clinical diagnostics. Whether it’s yield, accuracy, or sample conditions, engineered enzymes can help provide better results.
Learn MoreSustainable bioprocesses enabled by enzymes can eliminate the use of hazardous reagents, remove wasteful steps, and reduce overall manufacturing cost for API production, food ingredients production, and other industrial operations. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.
Marcus Rohovie, Sr. Scientist at Codexis, presented a poster at the ASGCT Annual Meeting that highlights the potential of engineered transgenes to offer improved efficacy of Recombinant Factor VIII (FVIII) therapies in patients with Hemophilia A. The CodeEvolver® technology platform was used to identify variants of a B-domain deleted FVIII (FVIII-BDD) with superior properties as compared to the wild-type enzyme.
View Poster